Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing therapeutics for liver and viral diseases.
ALGS | US
Overview
Corporate Details
- ISIN(s):
- US01626L2043
- LEI:
- Country:
- United States of America
- Address:
- ONE CORPORATE DR., 2ND FLOOR, 94080 SOUTH SAN FRANCISCO
- Website:
- https://www.aligos.com/
Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for liver and viral diseases. The company leverages expertise in medicinal chemistry and biology to create differentiated, best-in-class drug candidates for conditions with significant unmet medical needs. Its development pipeline features Pevifoscorvir sodium, an oral small molecule capsid assembly modulator (CAM-E) for chronic hepatitis B (CHB), and ALG-055009, an oral small molecule thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH). Aligos aims to develop therapies with enhanced pharmacologic properties suitable for both monotherapy and combination treatment regimens.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Aligos Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aligos Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aligos Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
